SCHEMBL6173567

SCHEMBL6173567

CC1(Cc2ccnc3cccc(Cl)c23)NC(=O)N(c2ccc(S(=O)(=O)C(F)(F)F)cc2)C1=O

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.51
AR P10275 6/20 0.35
HTT P42858 1/20 0.35
ITGAL P20701 1/20 0.34
LMNA P02545 2/20 0.33
MAPT P10636 2/20 0.33
KMT2A Q03164 1/20 0.33
CYP2C9 P11712 1/20 0.32
THRB P10828 1/20 0.31
TP53 P04637 1/20 0.31
TRPV3 Q8NET8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6172368 0.90 IGF1R (0.52) IGF1RARITGALKMT2ATHRB
SCHEMBL6173676 0.90 IGF1R (0.52) IGF1RARITGALMAPTKMT2A
SCHEMBL6172915 0.90 IGF1R (0.51) IGF1RARITGALLMNAKMT2A
SCHEMBL6169082 0.88 IGF1R (0.50) IGF1RARHTTMAPTKMT2A
SCHEMBL6175292 0.86 IGF1R (0.65) IGF1RARITGALKMT2ATP53
SCHEMBL6171503 0.86 IGF1R (0.65) IGF1RARITGALKMT2ATP53
SCHEMBL6173468 0.86 IGF1R (0.49) IGF1RARHTTITGALLMNA
SCHEMBL6174017 0.85 IGF1R (0.43) IGF1RAR
SCHEMBL6173958 0.85 AR (0.35) IGF1RARHTTITGAL
Trifluoroacetic Acid SCHEMBL17558350 0.82 IGF1R (0.60) IGF1RARITGALLMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1599464-A2 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS Aventis Pharma S.A. (FR) 2005-11-30 EP disclosed
WO-2004070050-A2 CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2004-08-19 WO disclosed